[EN] NLRP3 INFLAMMASOME INHIBITORS [FR] INHIBITEURS DE L'INFLAMMASOME NLRP3
摘要:
Disclosed herein are NLRP3 inflammasome inhibitors and compositions thereof. Also disclosed herein are methods including administering a therapeutically effective amount of a composition comprising at least one NLRP3 inflammasome inhibitor to a subject in need thereof.
[EN] ß-BORATION OF ALKENE AND ALKYNE INTERMEDIATES<br/>[FR] ß-BORATION D'INTERMÉDIAIRES D'ALCÈNE ET D'ALCYNE
申请人:LEK PHARMACEUTICALS
公开号:WO2013150125A1
公开(公告)日:2013-10-10
The present invention relates to the field of organic chemistry, and in particular to the preparation of β-borated compounds. These β-borated compounds can be used as intermediates in the synthesis pharmaceutically active agents such as sitagliptin.
A simple and convenient synthesis of β-haloketones
作者:John N. Marx
DOI:10.1016/s0040-4020(01)88558-6
日期:1983.1
quantitative method to synthesize β-halo-ketones is described (eqn 2) which utilizes the reaction of an enone with a tetraalkyl ammonium halide in anhydrous trifluoro acetic acid. The method is especially convenient for the preparation of β-iodoketones.
MARX, J. N., TETRAHEDRON, 1983, 39, N 9, 1529-1531
作者:MARX, J. N.
DOI:——
日期:——
Preparation and Reactivities of (η<sup>3</sup>-1- and 2-Trimethylsiloxyallyl)Fe(CO)<sub>2</sub>NO Complexes. Intermediates Functioning as Equivalents of β- and α-Acyl Carbocations and Acyl Carbanions
作者:Keiji Itoh、Saburo Nakanishi、Yoshio Otsuji
DOI:10.1246/bcsj.64.2965
日期:1991.10
(η3-1- and 2-Trimethylsiloxyallyl)Fe(CO)2NO complexes were prepared by the reaction of the corresponding siloxyallylic halides with Bu4N[Fe(CO)3NO]. These complexes reacted with both of carbon nucleophiles and carbon electrophiles preferentially at the less hindered sites of the allylic ligands. In these reactions, (η3-1-trimethylsiloxyallyl)Fe(CO)2NO complexes served as synthetically equivalent synthons
[EN] NLRP3 INFLAMMASOME INHIBITORS<br/>[FR] INHIBITEURS DE L'INFLAMMASOME NLRP3
申请人:[en]VENATORX PHARMACEUTICALS, INC.
公开号:WO2023230002A1
公开(公告)日:2023-11-30
Disclosed herein are NLRP3 inflammasome inhibitors and compositions thereof. Also disclosed herein are methods including administering a therapeutically effective amount of a composition comprising at least one NLRP3 inflammasome inhibitor to a subject in need thereof.